… The scale depicts doubling doses of inhaled corticosteroid. The data were analyzed using
multiple regression analysis of slopes, depicting the line of best fit for each drug. The slope …

… as “high responders,” developing IOP rises of greater … inhaled corticosteroids. The purpose
of the current report was to investigate the relationship between use of inhaled corticosteroids …

… Inhaled corticosteroids (ICS) are considered the most effective asthma therapy, but
concerns remain about side effects. The ideal ICS would have a larger therapeutic ratio than …

… Despite evidence demonstrating generally excellent therapeutic ratios for inhaled corticosteroids
(ICSs) in asthma treatment, many clinicians … Developing the ideal inhaled corticosteroid …

… Patients at high risk of developing type 2 DM from obesity compounded by another risk
factor, such as ethnicity and/or a positive family history, should be tested after ICS treatment is …

… for a spacer on the development of adverse gastrointestinal … patients prescribed inhaled
corticosteroids have a slight risk for … Oral corticosteroids have been implicated as a risk factor for …

… Oral corticosteroids are a known risk factor for the development of subcapsular cataracts,
with risk influenced by daily cumulative dose, age, and ethnic origin. The systematic review 6 …

… , but risk increases with high-dose ICSs. Although several new drugs are being developed
and … for asthma, but more effective initial controller therapy could be developed for COPD. …

… For systemic corticosteroids, the increased risk for the development of posterior subcapsular
cataract is well established [18, 19]. Despite anecdotal reports [20, 21] suggesting an …

There is a considerable amount of evidence that supports the possibility of an increased risk
of pneumonia associated with prolonged use of inhaled corticosteroids (ICS) in patients …